We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Register for real-time alerts, custom portfolio, and market movers
The current STX market cap is 11.44M. The company's latest EPS is GBP -0.0522 and P/E is -0.28.
| Year End 31 December 2022 | 2018 | 2019 | 2020 | 2021 | 2022 |
|---|---|---|---|---|---|
| GBP (£) | GBP (£) | GBP (£) | GBP (£) | GBP (£) | |
| Total Revenue | 11.88M | 719k | 10.39M | 1.52M | 4.47M |
| Operating Income | -5.16M | -9.04M | -2.15M | -20.29M | -40.41M |
| Net Income | -1.79M | -8.8M | -2.63M | -19.68M | -40.44M |
| Year End 31 December 2022 | 2018 | 2019 | 2020 | 2021 | 2022 |
|---|---|---|---|---|---|
| GBP (£) | GBP (£) | GBP (£) | GBP (£) | GBP (£) | |
| Total Assets | 43.53M | 36.32M | 32.53M | 44.41M | 22.07M |
| Total Liabilities | 3.1M | 4.17M | 2.25M | 3.72M | 16.65M |
| Total Equity | 40.43M | 32.15M | 30.28M | 40.69M | 5.43M |
| Year End 31 December 2022 | 2018 | 2019 | 2020 | 2021 | 2022 |
|---|---|---|---|---|---|
| GBP (£) | GBP (£) | GBP (£) | GBP (£) | GBP (£) | |
| Operating | 151k | -4.07M | -1.4M | -18.26M | -17.31M |
| Investing | -3.3M | -1.37M | -20k | -2.05M | -1.87M |
| Financing | -379k | -203k | -47k | 27.71M | 7.01M |
| Market Cap | 11.44M |
| Price to Earnings Ratio | -0.28 |
| Price to Sales Ratio | 2.53 |
| Price to Cash Ratio | 4.08 |
| Price to Book Ratio | 2.1 |
| Dividend Yield | - |
| Shares Outstanding | 775.43M |
| Average Volume (1 week) | 3.63M |
| Average Volume (1 Month) | 3.54M |
| 52 Week Change | -77.99% |
| 52 Week High | 12.75 |
| 52 Week Low | 1.475 |
| Spread (Intraday) | 0.05 (3.33%) |
| Company Name | Shield Therapeutics Plc |
| Address |
northern design centre newcastle upon tyne NE8 3DF |
| Website | https://www.shieldtherapeutics.com |
| Industry | pharmaceutical preparations (2834) |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions
Hot Features
Premium
